Venus Remedies Ltd
Ticker: VENUSREM
Risky
48/100
☆ Add to Watchlist
Investing Reference
Price
434.35
Market Cap
580.60
Debt/Equity
0.0030
ROE %
8.643
PB
1.0350
Promoter %
41.760
Pledge %
0.000
1Y Rev Growth %
10.722
5Y Rev Growth %
12.540
NP Margin %
6.675
NP Margin 5Y Avg %
6.601
Trading Reference
1M Return %
-0.978
6M Return %
43.303
1Y Return %
39.461
% Away 52W High
30.724
% Away 52W Low
60.722
Daily Volume
6542
Investment Verdict
Buy
Score 75/100 · Position size: 40%
Long-term fundamentals are strong. Suitable for investors with a 1–3+ year horizon.
Trading Verdict
Avoid
Score 35/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
Summary
Venus Remedies Ltd shows potential for growth in the pharmaceutical sector, driven by innovative products and expanding international presence.
✅ Positives
- Strong pipeline of new products
- Growing export markets in multiple countries
- Focus on R&D for competitive advantage
⚠️ Negatives
- High dependency on a few key markets
- Regulatory challenges in international expansion
- Volatility in raw material prices
Verdict
Moderate growth potential with some risks.
Recommendation: Consider buying on dips.
Upside Probability: 30% | Downside Probability: 20%
Last generated: 31/10/2025
More Options
S
Shri Venkatesh Refineries Ltd
The company faces several challenges, including inconsistent growth and profitability metrics, which make it a risky investment at this time.
View details
S
Swiss Military Consumer Goods Ltd
The stock presents several risks with inconsistent growth and profitability metrics, making it a risky investment.
View details
U
Uni-Abex Alloy Products Ltd
The stock presents several risks with inconsistent growth and moderate profitability metrics, suggesting caution for investors.
View details
U
UTI Nifty Next 50 Exchange Traded Fund
The UTI Nifty Next 50 ETF presents a decent investment opportunity with growth potential, but investors should be cautious of valuation and execution risks.
View details
S
Speciality Restaurants Ltd
While Speciality Restaurants Ltd operates in a growing sector, its inconsistent growth and profitability metrics raise concerns. Caution is advised due to competitive pressures and execution risks.
View details
H
Harita Seating Systems Ltd
Harita Seating Systems Ltd shows potential but faces challenges in growth consistency and market positioning.
View details
I
Iris Clothings Ltd
Iris Clothings Ltd presents several risks with inconsistent growth and profitability metrics, alongside governance concerns, making it a risky investment at this time.
View details
D
Delton Cables Ltd
Delton Cables Ltd shows potential in a growing sector, but faces challenges in profitability and valuation metrics.
View details
Z
Zodiac Energy Ltd
Zodiac Energy Ltd presents a mixed outlook with significant risks, particularly in growth consistency and market sentiment.
View details
R
Radiant Cash Management Services Ltd
Radiant Cash Management Services Ltd shows potential in a growing sector, but faces challenges in profitability and valuation metrics.
View details
K
Kerala Ayurveda Ltd
Kerala Ayurveda Ltd shows potential in a growing sector, but faces challenges in execution and profitability.
View details
B
Borana Weaves Ltd
Borana Weaves Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
B
Bella Casa Fashion & Retail Ltd
Bella Casa Fashion & Retail Ltd shows potential but faces challenges in growth consistency and market sentiment.
View details
S
Sical Logistics Ltd
Sical Logistics Ltd shows potential in a growing sector but faces challenges in execution and market sentiment.
View details
K
Kiran Vyapar Ltd
Kiran Vyapar Ltd shows some potential but faces significant challenges in growth and profitability metrics. Caution is advised.
View details
G
GVK Power & Infrastructure Ltd
GVK Power & Infrastructure Ltd presents significant risks with inconsistent performance and high debt levels, making it a risky investment.
View details
Business Overview
Venus Remedies Ltd is a leading Indian pharmaceutical company specializing in innovative and high-quality healthcare solutions. Catering to hospitals, clinics, and healthcare providers, it focuses on critical care and specialty products that enhance patient outcomes. With a commitment to research and development, Venus Remedies stands out for its advanced formulations and global reach. The company is dedicated to improving healthcare standards and accessibility, making it a trusted partner in the medical community.
- Established leader in the pharmaceutical sector
- Focus on critical care and specialty products
- Strong commitment to research and development
- Global presence with a focus on quality
- Enhancing patient outcomes through innovation
Investment Thesis
Venus Remedies Ltd stands out as a compelling investment due to its strong promoter credibility, significant growth potential in digital services, and attractive valuation compared to peers. These factors position the company for sustainable growth and long-term value creation.
- Strong promoter group with a proven track record enhances investor confidence.
- Expanding digital services segment presents a robust growth runway.
- Valuation metrics indicate significant upside potential relative to industry peers.
- Focus on innovation and R&D strengthens competitive positioning.
- Solid financial performance and strategic initiatives drive future growth.
Opportunity vs Risk
Opportunities
- Strong growth in pharmaceutical sector
- Expansion into international markets
- Innovative product pipeline
- Strategic partnerships with healthcare firms
Risks ⚠️
- Regulatory challenges in drug approvals
- Intense competition in the industry
- Fluctuating raw material costs
- Dependence on key patents
Peer Perspective
Venus Remedies Ltd trades at a discount to peers like Cipla and Sun Pharma, reflecting concerns over margin stability. A sustained improvement in operational efficiency could trigger a rerating in the stock.
AI FAQs for Retail Users
- Q: What does Venus Remedies Ltd do?A: Venus Remedies Ltd specializes in developing and manufacturing pharmaceutical products, particularly in the field of critical care and anti-infectives.
- Q: Is Venus Remedies Ltd a profitable company?A: Profitability can vary; it's important to review the latest financial reports and trends.
- Q: What are the risks of investing in Venus Remedies Ltd?A: Risks include market competition, regulatory changes, and potential fluctuations in demand for pharmaceutical products.
- Q: How can I buy shares of Venus Remedies Ltd?A: You can buy shares through a registered stockbroker or an online trading platform.
- Q: Where can I find more information about Venus Remedies Ltd?A: You can check their official website, financial news platforms, and stock market analysis sites.
📊 Stock Investment Checklist (100 Points)
Venus Remedies Ltd • Updated: 2025-09-18 01:35:38
-
8BusinessHighThe company operates in the pharmaceutical sector, which is generally future-ready with a clear model focused on niche markets.
-
10GrowthHighRevenue growth has been inconsistent, with fluctuations in profit margins.
-
10ProfitabilityHighROE and ROCE are moderate, with operating cash flow showing some volatility.
-
9ValuationHighValuation metrics are slightly above peers, indicating potential overvaluation.
-
7BalanceHighThe balance sheet shows manageable debt levels but limited liquidity.
-
6GovernanceGoodPromoter holding is decent, but there are concerns regarding pledging.
-
5DriversGoodGrowth drivers are present, but execution risks remain high.
-
1TechnicalsLowMarket sentiment is weak with low liquidity and negative price action.
Final Score & Verdict
Score 48 / 100
• Risky
Venus Remedies Ltd presents a mixed outlook with significant risks overshadowing its potential growth. Investors should exercise caution.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 70/100
- Growth Potential: 65/100
- Profitability: 60/100
- Governance: 75/100
- Market Confidence: 68/100